BeiGene News
- July 27, 2020Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
- July 20, 2020Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
- July 17, 2020BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
- July 15, 2020BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
- July 12, 2020BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
- July 2, 2020BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
- BeiGene Facts
- 2010Founded
- NASDAQ: BGNE
HKEX: 06160Listings - 6Internally Developed
Clinical Candidates - 5Marketed
Products
in China - 1Approved
products
in the U.S. - 4100+Global Team
2010
- BeiGene was founded as a research and development company
2012
- Began work on an anti-PD-1 antibody and a BTK inhibitor
2014
- Started clinical trials of pamiparib and zanubrutinib
2016
- Went public on the Nasdaq, with $182 million initial public offering
2018
- Established first European office in Switzerland
- 50+ ongoing or planned clinical trials
2019
- Received first FDA approval for BRUKINSA™ (zanubrutinib)
- Received first approval for tislelizumab in China
Partnering
Partnerships that Extend Around the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.
Our Patients
Our Commitment to Patients
At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.